Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.

Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.

<h4>Background</h4>Heterologous boost vaccination has been proposed as an option to elicit stronger and broader, or longer-lasting immunity. We assessed the safety and immunogenicity of heterologous immunization with a recombinant adenovirus type-5-vectored Coronavirus Disease 2019 (COVI...

Full description

Bibliographic Details
Main Authors: Pengfei Jin, Xiling Guo, Wei Chen, Shihua Ma, Hongxing Pan, Lianpan Dai, Pan Du, Lili Wang, Lairun Jin, Yin Chen, Fengjuan Shi, Jingxian Liu, Xiaoyu Xu, Yanan Zhang, George F Gao, Cancan Chen, Jialu Feng, Jingxin Li, Fengcai Zhu
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022-05-01
Series:PLoS Medicine
Online Access:https://doi.org/10.1371/journal.pmed.1003953

Internet

https://doi.org/10.1371/journal.pmed.1003953

Similar Items